# A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer

> **NCT01217177** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 14 (actual)

## Conditions studied

- Locally Advanced Cervical Cancer

## Interventions

- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT01217177
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2015-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01217177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01217177, "A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01217177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*